» Articles » PMID: 39717553

Activation of Cannabinoid Receptor 2 by Turmeric Oleoresin Reduces Inflammation and Oxidative Stress in an Osteoarthritis Model

Overview
Journal Front Pharmacol
Date 2024 Dec 24
PMID 39717553
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Osteoarthritis (OA) is a chronic degenerative joint disease characterized by the progressive degradation of articular cartilage, resulting in pain and reduced mobility. Turmeric ( L.) has been widely recognized for its anti-inflammatory and antioxidant properties, but the molecular mechanisms underlying its therapeutic effects remain inadequately explored. This study investigates the potential of turmeric oleoresin (TUR) to activate Cannabinoid Receptor 2 (CBR2) and its role in mediating anti-inflammatory and antioxidant effects in an OA model.

Material And Methods: Molecular docking and cAMP quantification assays were used to evaluate TUR's agonistic activity on CBR2. Human chondrosarcoma cells (SW-1353) were treated with TUR under oxidative stress induced by menadione or inflammatory conditions simulated with IL-1β and TNF-α. The effects of TUR were assessed in the presence and absence of the CBR2 antagonist SR144528. Outcomes included changes in reactive oxygen species (ROS) production, inflammatory marker expression, oxidative defense markers and endocannabinoid system components and receptors.

Results: TUR was confirmed as a CBR2 agonist and significantly reduced ROS production, downregulated pro-inflammatory cytokines (IL-6, COX-2, metalloproteases), and suppressed signaling pathways such as NFKB1, ERK 1/2, and c-Myc. These effects were reversed upon CBR2 inhibition. TUR also enhanced HMOX-1 expression and modulated endocannabinoid-related enzymes, highlighting its impact on oxidative stress and the endocannabinoid system.

Discussion: These findings suggest that CBR2 activation is central to TUR's anti-inflammatory and antioxidant effects. By modulating key pathways and endocannabinoid system components, TUR demonstrates potential as a novel therapeutic agent for OA management. Future studies could explore its clinical applications and further validate its molecular mechanisms .

References
1.
Mannino F, Pallio G, Imbesi C, Scarfone A, Puzzolo D, Micali A . Beta-Caryophyllene, a Plant-Derived CB2 Receptor Agonist, Protects SH-SY5Y Cells from Cadmium-Induced Toxicity. Int J Mol Sci. 2023; 24(20). PMC: 10607613. DOI: 10.3390/ijms242015487. View

2.
Kolasinski S, Neogi T, Hochberg M, Oatis C, Guyatt G, Block J . 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72(2):149-162. PMC: 11488261. DOI: 10.1002/acr.24131. View

3.
Russo E . Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol Sci. 2016; 37(7):594-605. DOI: 10.1016/j.tips.2016.04.005. View

4.
Shokri-Mashhadi N, Bagherniya M, Askari G, Sathyapalan T, Sahebkar A . A Systematic Review of the Clinical Use of Curcumin for the Treatment of Osteoarthritis. Adv Exp Med Biol. 2021; 1291:265-282. DOI: 10.1007/978-3-030-56153-6_16. View

5.
Djouad F, Rackwitz L, Song Y, Janjanin S, Tuan R . ERK1/2 activation induced by inflammatory cytokines compromises effective host tissue integration of engineered cartilage. Tissue Eng Part A. 2009; 15(10):2825-35. PMC: 2792059. DOI: 10.1089/ten.TEA.2008.0663. View